期刊文献+

依替米星+美罗培南对多药耐药铜绿假单胞菌肺部感染的治疗分析 被引量:2

Analysis of etilmicin combined with meropenem in the treatment of pulmonary infection caused by multidrug resistant pseudomonas aeruginosa
暂未订购
导出
摘要 目的:分析依替米星+美罗培南对多药耐药铜绿假单胞菌肺部感染的治疗效果。方法:2017年9月-2019年9月收治多药耐药铜绿假单胞菌肺部感染患者66例,随机分为两组,各33例。对照组采用依替米星治疗,观察组采用依替米星联合美罗培南治疗,比较两组治疗效果。结果:观察组体温、WBC、PCT、CRP水平低于对照组,PaO_(2)/FiO_(2)水平高于对照组,差异有统计学意义(P<0.05)。结论:依替米星+美罗培南对多药耐药铜绿假单胞菌肺部感染的治疗效果显著,不仅能改善临床指标水平,还能降低炎性因子水平。 Objective:To analyze the therapeutic effect of etilmicin combined with meropenem in the treatment of pulmonary infection of multidrug resistant pseudomonas aeruginosa.Methods:From September 2017 to September 2019,66 patients with pulmonary infection caused by multidrug resistant pseudomonas aeruginosa were selected,they were randomly divided into the two groups with 33 cases in each group.The control group was treated with etilmicin.The observation group was treated with etilmicin combined with meropenem.The therapeutic effects of the two groups were compared.Results:The levels of body temperature,WBC,PCT and CRP in the observation group were lower than those in the control group,while the level of PaO_(2)/FiO_(2) was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion:Etilmicin combined with meropenem is effective in the treatment of pulmonary infection caused by multidrug resistant pseudomonas aeruginosa,which can not only improve the clinical index,but also reduce the level of inflammatory factors.
作者 周丽华 Zhou Lihua(The 983rd Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Tianjin 300142)
出处 《中国社区医师》 2021年第12期69-70,共2页 Chinese Community Doctors
关键词 依替米星 美罗培南 多药耐药铜绿假单胞菌肺部感染 治疗效果 Etilmicin Meropenem Pulmonary infection caused by multidrug resistant pseudomonas aeruginosa Therapeutic effect
  • 相关文献

参考文献14

二级参考文献92

  • 1中华医学会,中华医院管理学会药事管理专业委员会,中国药学会医院药学专业委员会.抗菌药物临床应用指导原则[J].中华医学杂志,2004,84(23):2026-2056. 被引量:154
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33093
  • 3Paterson DL. The epidemiological profile of infections with multidrug-resistant aenoginosa and acinetobacter species[J]. Clin Infect Dis ,2006,4i(Supplz) :S43-48.
  • 4Vicente pintado Lucia Garcia san Miguel Fabio grill et al . Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria [J]. J Infection , 2008,56,185-190.
  • 5Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents [J]. Inflect Immum , 1996,64(12) :4922-4927.
  • 6CLSI. Performance standards for antimicrobial susceptibility testing: Seventeenth informational supplement (M100-S17) [s]. 2007.
  • 7Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare[J]. Clin Infect Dis ,2002,34(5):634-640.
  • 8Hsueh PR, Teng LJ, Chen CY, at al. Pandrug-resistant acinetobacter baumannii causing nosocomial imfections in a university hospital,Taiwan[J]. Emerg Infect Dis ,2002 8(8) 827-832.
  • 9Gales AC,Jones RN,Sader Hs. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli:report from the SENTRY. antimicrobial surveillance programme(2001 - 2004) [J]. Clin Microbial Infect ,2006,12(4) :315-321.
  • 10Falagas ME, KasiaRou SK, Tsiodras S, et al . The use of intravenous and aerosolized polymymxins for the treatment of infections in critically ill patients : a review of the recent literature[J]. Clin Ailed Res ,2006,4(2) :138-146.

共引文献127

同被引文献20

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部